


Horizon2020

SC1 – Health, Demographic change and
Wellbeing - Opportunità per l'area
“Salute (2018-2020)”



Bruno MOURENZA

Horizon 2020

Punto di Contatto Nazionale SC1

H2020/ The Three Pillars



Struttura del programma H2020

Excellent Science

- **European Research Council**
 - Frontier research by the best individual teams
- **Future and Emerging Technologies**
 - Collaborative research to open new fields of innovation
- **Marie Skłodowska Curie actions**
 - Opportunities for training and career development
- **Research infrastructures** (including e-infrastructure)
 - Ensuring access to world-class facilities

Industrial Technologies

- **Leadership in enabling and industrial technologies**
 - ICT, nanotechnologies, materials, biotechnology, manufacturing, space
- **Access to risk finance**
 - Leveraging private finance and venture capital for research and innovation
- **Innovation in SMEs**
 - Fostering all forms of innovation in all types of SMEs



Societal Challenges

- **Health, demographic change and wellbeing**
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Secure societies



European Institute of Innovation and Technology (EIT)


Spreading Excellence and Widening Participation

Science with and for society

Joint Research Center (JRC)




Health in H2020



*Health solutions can imply
different phases of research and
innovation*

STRUCTURE OF THE PROGRAMME: WHERE HEALTH could fit?





2° PILLAR

INDUSTRIAL LEADERSHIP



Connections to Health in Pillar II

Industrial Technologies

- **Leadership in enabling and industrial technologies**
 - ICT, nanotechnologies, materials, biotechnology, manufacturing, space
- **Access to risk finance**
 - Leveraging private finance and venture capital for research and innovation
- **Innovation in SMEs**
 - Fostering all forms of innovation in all types of SMEs

ICT for health

ICT

Nano for health

Nano-technology



Materials for health

Materials



HEALTH

Red Biotech

Biotech





3° PILLAR

SOCIETAL CHALLENGES






HEALTH implications in Societal Challenges

Societal Challenges

- **Health, demographic change and wellbeing**
- **Food security, sustainable agriculture, marine and maritime research & the bioeconomy**
- **Secure, clean and efficient energy**
- **Smart, green and integrated transport**
- **Climate action, resource efficiency and raw materials**
- **Inclusive, innovative and reflective societies**
- **Security society**





SC1. HEALTH, DEMOGRAPHIC CHANGE AND WELLBEING



Nuova struttura del WP SC 1 2018-2020

Call 1. Better health and care, economic growth and sustainable health systems (RTD)

- 1.1 Personalised medicine
- 1.2 Innovative health and care industry
- 1.3 Infectious diseases and improving global health
- 1.4 Innovative health and care systems – Integration of care
- 1.5 Decoding the role of the environment for health and well-being

Call 2. Digital Transformation in Health and Care (CNECT)

Call 3. Trusted digital solutions and cybersecurity in health and care (CNECT)

Other actions (including prizes)

2020: Calls 1. and 2. and Other actions - only titles, no text

Work Programme SC1 – 2018-2020:

http://ec.europa.eu/research/participants/data/ref/h2020/wp/2018-2020/main/h2020-wp1820-health_en.pdf



Call 1 - Better Health and care, economic growth and sustainable health systems

aims to achieve:

- Develop sustainable health and care systems and growth opportunities for the health and care related industries;
- Health and care systems and services more accessible, responsive and efficient

The scope of the call may range from **prevention, diagnosis, stratified approaches, predictive toxicology, novel and repurposed therapeutic approaches, including medical technologies and advanced therapies, cohorts and registries-based research, integration of care and systemic digital solutions for health and ageing well**



Call 2 - Digital transformation in Health and Care

aims to achieve:

☐ transformation of health and care services to more digitised, person-centred and community-based care models.

☐ Maximize the potential of the digital economy in the health and care sectors

☐ 2 relevant priorities to the EC and to the European Cloud Initiative and the European Free Flow of Data Initiative

The call **will address eHealth, mobile health (mHealth) and Information and Communication Technologies (ICT) for Active and Healthy Ageing.**



Call 3 - Trusted digital solutions and Cybersecurity in Health and Care

aims to achieve:


- ❑ Cybersecurity to assure data privacy, security and protection of health and care infrastructures.
- ❑ contribute to the following Focus Areas from WP ICT 2018-20: 'Digitising and transforming European industry and services' and 'Boosting the effectiveness of the Security Union'.

It addresses the *need for secure and user-driven ICT-based solutions in early risk detection and interventions with big data approaches* that enable aggregation of a variety of new and existing data sources such as medical records, registries, social platforms and other environmental, physiological and behavioural data, including data from large scale pilots on smart living environments.

Tempi di pubblicazione, le scadenze, l'uso del single o doppio stage?

➤ Previsti bandi SINGLE STAGE e DOPPIO STAGE*

Call	2018		2019		2020
	Opening	Deadline	Opening	Deadline	
1 Better Health and care, economic growth and sustainable health systems DG RTD	7 Nov 2017	6 Feb 2018*	26 Jul 2018	2 Oct 2018*	<i>To be defined</i>
		4 Sett 2018*		16 Apr 2019*	
		18 Apr 2018	16 Apr 2019		
2 Digital transformation in Health and Care DG Connect	7 Nov 2017	24 Apr 2018	26 Jul 2018	14 Nov 2018	
			16 Oct 2018	24 Apr 2019	
3 Trusted digital solutions and Cybersecurity in Health and Care DG Connect	7 Nov 2017	24 Apr 2018	26 Jul 2018	14 Nov 2018	




The contribution to Focus Areas will be EUR 186.50 million for 'Digitisation' and EUR 71 million for 'Security Union'.

**Other Actions excluded*

Quali sono Gli strumenti utilizzati (RIA, IA , PCP , Eranets...?) ?
 Ci sono progetti di grandi, medie , piccole dimensioni?
 Ci sono evidenti aree di interesse sulla cooperazione extra UE (USA, ASIA, ..AFRICA..ecc?)

- 48 topics (2018-2019) + 21 nel 2020 – senza considerare *Other actions*. (9 +7)
- Presenti RIA, IA, CSA, PCP, PPI, Era-Net, EJP

No. of topics vs Funding scheme



- Presenti progetti di piccoli e grandi dimensioni (da 1,5 3, 6, 10, a 50 mill. Eur)
- Cooperazione internazionale maggiormente implementata attraverso Joint Calls (CELAC, Russia, China, Canada) e in aree di rilevante interesse per EU:
 - *human data on personalized medicine approaches with Canada*
 - *non-communicable diseases CELAC*
 - *HIV, tuberculosis and/or hepatitis C with Russia*
 - *Strategic collaboration on healthcare R&I with China*

Strategic Initiatives around HEALTH



Innovative Medicines Initiative 2
www.imi.europa.eu



**European Innovation Partnership
on Active and Healthy Ageing**
<https://webgate.ec.europa.eu/eipaha>



Active and Assisted Living 2
www.aal-europe.eu



**European & Developing Countries
Clinical Trials Partnership (EDCTP2)**
www.edctp.org




innovative
medicines
initiative



Business Support on Your Doorstep



IMI 2 budget



EFPIA = **E**uropean **F**ederation of **P**harmaceutical **I**ndustries and **A**ssociation

* Imaging, Diagnostics, IT for health etc.

Strategic Research Agenda

- Antimicrobial resistance
- Osteoarthritis
- Cardiovascular diseases
- Diabetes/Metabolic disorders
- Neurodegenerative diseases
- Psychiatric diseases
- Respiratory diseases
- Immune-mediated diseases
- Ageing-associated diseases
- Cancer
- Rare/Orphan Diseases
- Vaccines



The right prevention and treatment
 for the right patient at the right time

Strategic Research Agenda for
 Innovative Medicines Initiative 2

**Aligned with
 WHO priorities**



Who is eligible for funding?

- Academic institutions
- Small & medium-sized enterprises (SMEs)
- Mid-sized enterprises (\leq €500m)
- Non-profit organisations e.g. research organisations, patient organisations, NGOs, public bodies, intergovernmental organisations etc.

Established in:

- EU Member States
- Associated Countries

Other countries:

No funding **unless**

- participation deemed essential by IMI for carrying out the action
- **Annual Work Plan / Calls documents**

New! At least three legal entities

IMI partner search tool: <https://cloud.imi.europa.eu/web/eimi-pst>



IMI 2 – Call 8 includes the following topic:

➤ *Ebola and other filoviral haemorrhagic fevers (Ebola+)*
programme: future outbreaks

The indicative budget for the entire period of 2 years is **€70 million**.

Deadlines

The Call will remain **open for two years**, with the following **cut-off dates**:

- 16 March 2016
- 15 September 2016
- 16 March 2017
- 14 September 2017
- 15 March 2018



Topics for IMI Call 13 – Deadline 28th February



<http://www.imi.europa.eu/apply-funding/open-calls/imi2-call-13>

- Topic 1: Assessment of the uniqueness of **diabetic** cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
- Topic 2: Genome-Environment Interactions in **Inflammatory Skin Disease**
- Topic 3: The value of diagnostics to combat **antimicrobial resistance** by optimising antibiotic use
- Topic 4: Mitochondrial Dysfunction in **Neurodegeneration**
- Topic 5: Support and coordination action for the projects in the **neurodegeneration** area of the Innovative Medicines Initiative
- Topic 6: A sustainable European induced pluripotent **stem cell** platform
- Topic 7: Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
- Topic 8: **Human tumour** microenvironment immunoprofiling
- Topic 9: ConcePTION – Continuum of Evidence from **Pregnancy Exposures, Reproductive Toxicology and Breastfeeding** to Improve Outcomes Now
- Topic 10: Improving the preclinical prediction of adverse effects of pharmaceuticals on the **nervous system**
- Topic 11: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel **safety biomarkers in clinical trials** and diagnosis of disease
- Topic 12: Pilot programme on a Clinical Compound Bank for Repurposing: **Cardiovascular diseases and diabetes**
- Topic 13: Pilot programme on a Clinical Compound Bank for Repurposing: **Respiratory diseases**
- Topic 14: Pilot programme on a Clinical Compound Bank for Repurposing: **Neurodegenerative diseases**
- Topic 15: Pilot programme on a Clinical Compound Bank for Repurposing: **Rare/orphan diseases**

Interested in applying? Read our [tips for applicants](#) and [advice on finding project partners](#)

www.apre.it

Stay in touch

- Visit our website
www.imi.europa.eu
- Sign up to our newsletter
bit.ly/IMInewsletter
- Follow us on Twitter
[@IMI_JU](https://twitter.com/IMI_JU)
- Join our LinkedIn group
bit.ly/LinkedInIMI
- E-mail us
infodesk@imi.europa.eu



The screenshot shows the IMI website homepage. At the top, there is a navigation bar with 'APRF' and links for 'Contact', 'Newsletter', and 'Links'. The main header features the IMI logo and the text 'innovative medicines initiative' next to a photograph of a diverse group of people in a laboratory setting. Below the header is a search bar and a navigation menu with links to 'Home', 'About IMI', 'Ongoing projects', 'Calls for proposals', 'News, Events & Media', and 'Reference documents'. A central section titled 'THE INNOVATIVE MEDICINES INITIATIVE' provides a brief overview of the organization's mission and its collaborative research focus. To the right, an 'IMI NEWSFLASH' section lists recent updates, including webinars and diagnostic tests. Below the main text are four buttons: 'PARTNER SEARCH', 'EDUCATION & TRAINING', 'SMALL & MEDIUM-SIZED ENTERPRISES', and 'INTELLECTUAL PROPERTY'. A featured article titled 'IMI LAUNCHES EBOLA+ PROGRAMME' is highlighted with a blue background and a 'more' link.



The screenshot displays the Twitter profile for the Innovative Medicines Initiative (@IMI_JU). The profile header includes the IMI logo and the text 'innovative medicines initiative'. Below this, the profile statistics are shown: 1,286 tweets, 838 following, 2,159 followers, 2 favorites, and 2 lists. The bio states: 'The Innovative Medicines Initiative (IMI) is a public-private partnership aiming to speed up the development of better and safer medicines for patients.' The location is listed as Brussels, the website as imi.europa.eu, and the account was joined in June 2010. There are 57 photos and videos available. The main content area shows a list of tweets, including a recent tweet about webinars and several tweets from November 6, 2014, regarding Ebola diagnostic tests and vaccine compliance. The bottom of the page features the website URL www.apic.it.



JPND

research

EU Joint Programme – Neurodegenerative Disease Research

EU Joint Programme – Neurodegenerative Disease Research

www.apre.it



Implementation Plan

A first-phase JPND Implementation Plan has been agreed for the **period of 2012-2014**. The plan has these major action areas:

Annual Calls for Proposals

Action Groups to determine research needs and opportunities

Action Groups to promote engagement, commitment and partnerships

Annual Calls for Proposals

JPND intends to launch Calls for proposals each year to address high priority areas in neurodegenerative disease research. Over the period of 2012-2014, it is anticipated that JPND will launch calls to address each of the following priority areas:

In general: Minimum 3 and maximum of 6 research groups (principal investigators) from at least 3 different countries of the funding organizations participating in this call

<http://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/open-calls/>

NEW Partnering Tool

<http://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/partnering-tool/>



JPND
research

EU Joint Programme – Neurodegenerative Disease Research

JPND Call for Proposals:

**"Multinational research projects on Health
and Social Care for Neurodegenerative
Diseases"**

<http://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/open-calls/health-and-social-care-2018/>

Submission deadline for pre-proposals:

March 6, 2018, 23:59h C.E.T.

For further information, please visit us on the web

<http://www.jpnd.eu/>



Ultimo bando pubblicato 2018

Deadline della pre-proposal 6 marzo 2018

"Multinational research projects on Health and Social Care for Neurodegenerative Diseases"

Sulle aree:

- Care pathways and services using the potential of patient involvement
- Factors influencing progression and prognosis of disease
- Outcome measures for patients and their informal caregivers
- Palliative care of patients
- Cost-effectiveness and affordability of interventions including ethical concerns

<http://www.neurodegenerationresearch.eu/wp-content/uploads/2018/01/JPND-HSC-Call-Text-2018.pdf>

Per l'Italia: solo IRCCS ammessi.



Active & Healthy Ageing

A European Innovation Partnership





I settori d'intervento prioritari sono stati individuati nel piano strategico di attuazione e nel piano operativo, adottati nel 2011 dal gruppo direttivo incaricato dell'avvio e dell'attuazione della partnership.

Per realizzare il piano tutti i soggetti interessati hanno iniziato a collaborare nell'ambito di gruppi d'azione.

- ✓ Action Group A1: Prescription and adherence action at regional level.
- ✓ Action Group A2: Personalized health management: Falls prevention.
- ✓ Action Group A3: Prevention of functional decline and frailty.
- ✓ Action Group B3: Integrated care for chronic diseases, including remote monitoring at regional level.
- ✓ Action Group C2: Interoperable independent living solutions.
- ✓ Action Group D4: Age friendly buildings, cities and environments.

Stakeholders wishing to get involved in the advancing of Specific Actions have formed **Action Groups** through the "Invitation for Commitment" application process.

In each Action Group, stakeholders commit to running a number of activities, contributing towards the headline target, starting with the creation and implementation of an Action Plan.

ERA-Nets finanziate in Horizon 2020 con partecipazione italiana



E-Rare-3	ERA-NET rare disease research implementing IRDiRC objectives	AGENCE NATIONALE DE LA RECHERCHE	FR
ERACoSysMed	ERACoSysMed - Collaboration on systems medicine funding to promote the implementation of systems biology approaches in clinical research and medical practice	FORSCHUNGSZENTRUM JUELICH GMBH	DE
JPco-fuND	ERA-NET for establishing synergies between the Joint Programming on Neurodegenerative Diseases Research and Horizon 2020	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)	FR
TRANSCAN-2	ERA-NET: Aligning national/regional translational cancer research programmes and activities	MINISTERO DELLA SALUTE	IT
ERA-CVD	ERA-NET on cardiovascular diseases to implement joint transnational research projects and set up international cooperations	DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV	DE
JPI-EC-AMR	ERA-NET for establishing synergies between the Joint Programming Initiative on Antimicrobial Resistance Research and Horizon 2020	VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL	SE
NEURON Cofund	ERA NET NEURON in the area of brain-related diseases and disorders of the nervous system	DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV	DE

Bandi SC1 - 2014-2015-2016-2017

No. topics	Budget Mill. EUR	Proposte presentate 	Proposte finanziate 	Tasso di successo 
62	2939,3	3373	343	10%

Partecipazione



No. Partecipanti italiani in proposte presentate	No. Partecipanti italiani finanziati	Tasso di successo partecipanti Italiani
3716	369	9,9%

Coordinamento



No. Proposte presentate a coordinamento italiano	No. Coordinamenti italiani finanziati	Tasso di successo coordinatori Italiani
459 (13% del totale EU)	26	5,6%



http://www.apre.it/media/459686/apre_panoramica_partecipazione_h2020.pdf

Grazie per l'attenzione

APRE
Agenzia per la Promozione della Ricerca Europea
via Cavour, 71
00184 - Roma
www.apre.it
Tel. (+39) 06-48939993
Fax. (+39) 06-48902550

Bruno MOURENZA
mourenza@apre.it

Health NCP